Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo

Published version of a preprint

Abstract

Well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) are among the most common subtypes of soft tissue sarcomas. Conventional systemic chemotherapy has limited efficacy and novel therapeutic strategies are needed to achieve better outcomes for patients. The cyclin-dependent kinase 4 (CDK4) gene is highly amplified in more than 95% of WD/DDLPS. In this study, we explored the role of CDK4 and the effects of NVP-LEE011 (LEE011), a novel selective inhibitor of CDK4/CDK6, on a panel of human liposarcoma cell lines and primary tumor xenografts. We found that both CDK4 knockdown by siRNA and inhibition by LEE011 diminished retinoblastoma (RB) phosphorylation and dramatically decreased liposarcoma cell growth. Cell-cycle analysis demonstrated arrest at G0-G1. siRNA-mediated knockdown of RB rescued the inhibitory effects of LEE011, demonstrating that LEE011 decreased proliferation through RB. Oral administration of LEE011 to mice bearing human liposarcoma xenografts resulted in approximately 50% reduction in tumor (18)F-fluorodeoxyglucose uptake with decreased tumor biomarkers, including RB phosphorylation and bromodeoxyuridine incorporation in vivo. Continued treatment inhibited tumor growth or induced regression without detrimental effects on mouse weight. After prolonged continuous dosing, reestablishment of RB phosphorylation and cell-cycle progression was noted. These findings validate the critical role of CDK4 in maintaining liposarcoma proliferation through its ability to inactivate RB function, and suggest its potential function in the regulation of survival and metabolism of liposarcoma, supporting the rationale for clinical development of LEE011 for the treatment of WD/DDLPS.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0387

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 114

Metadata

Authors
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., & Wagner, A. J.
Affiliations
  • 1Ludwig Center at Dana-Farber/Harvard, Harvard Medical School, Boston, Massachusetts.
  • Harvard University (US)
  • Johns Hopkins University (US)
  • Novartis (Switzerland) (CH)
  • Brigham and Women's Hospital (US)
  • Columbia University Irving Medical Center (US)
Venue
Molecular Cancer Therapeutics
Published
2014-09-01
Volume
13
Issue
9
Pages
2184-2193
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2157803976
Cited by
114
References
38
Citations by year
2026: 4 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 11 · 2021: 4 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 27 · 2016: 13 · 2015: 13
FWCI
14.15
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
CDK4/6 inhibition, liposarcoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, CDK4 amplification, retinoblastoma protein phosphorylation, G0/G1 cell cycle arrest, tumor xenografts, soft tissue sarcoma, antiproliferative activity, tumor growth inhibition
MeSH terms
Administration, Oral, Animals, Body Weight, Cell Cycle, Cell Differentiation, Cells, Cultured, Female, Humans, Immunohistochemistry, Liposarcoma, Male, Mice, Nude, Neoplasm Transplantation, Phosphorylation, Retinoblastoma Protein, Gene Dosage, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0387
The paper
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., & Wagner, A. J. (2014). Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.